A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the initial safety and effectiveness of an investigational
drug, niraparib, given to patients who have recently received platinum-based chemotherapy for
the treatment of prostate cancer. The study enrolls participants with history of advanced
prostate cancer that is growing despite standard hormonal therapies, such as
androgen-deprivation therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania